

FORM PTO-1449 (Modified)		ATTY. DOCKET NO.	SERIAL NO
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		C1039/7042	
		APPLICANT Krieg et al.	
		FILING DATE Herewith	GROUP 1635
OTHER ART			
(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)			
*	93	Adya N et al., Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB. <i>Proc Natl Acad Sci USA</i> 91(12):5642-6, 7 Jun 1994.	
*		Angier, N., Microbe DNA Seen as Alien By Immune System, <i>New York Times</i> , 4/11/95	
*		Azad RF et al., Antiviral Activity of a Phosphorothioate Oligonucleotide Complementary to RNA of the Human Cytomegalovirus Major Immediate-Early Region. <i>Antimicrobial Agents and Chemotherapy</i> , 37:1945-1954, September, 1993.	
*		Azuma, Biochemical and Immunological Studies on Cellular Components of Tubercle Bacilli, <i>Kekkaku</i> , Vol. 69, 9:45-55, 1992.	
*		Ballas ZK et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. <i>J Immunol</i> 157(5):1840-5, 1996.	
*		Bayever, E., Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial, <i>Antisense Res. & Dev.</i> (1993), 3:383-390.	
*		Bennett RM et al., DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA. <i>J Clin Invest</i> 76(6):2182-90, 1985.	
*		Berg DJ et al., Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. <i>J Clin Invest</i> 96(5):2339-47, 1995.	
*		Blanchard DK et al., Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages. <i>J Immunol</i> 136(3):963-70, 1986.	
*		Blaxter et al., Genes expressed in <i>Brugia malayi</i> infective third stage larvae. <i>Molecular and Biochemical Parasitology</i> , 77:77-93.	
*		Boggs RT et al., Characterization and modulation of immune stimulation by modified oligonucleotides. <i>Antisense Nucleic Acid Drug Dev</i> 7(5):461-71, Oct 1997.	
*		Branda RF et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides. <i>J. Lab Clin Med</i> 128(3):329-38, Sep 1996.	
*		Branda et al., Immune Stimulation by an Antisense Oligomer Complementary to the rev gene of HIV-1. <i>Biochemical Pharmacology</i> , Vol. 45, 10:2037-2043, 1993.	
*		Briskin M et al., Lipopolysaccharide-unresponsive mutant pre-B-cell lines blocked in NF-kappa B activation. <i>Mol Cell Biol</i> 10(1):422-5, Jan 1990.	
*		Chace, J. et al., Regulation of Differentiation in CD5+ and Conventional B Cells, <i>Clinical Immunology and Immunopathology</i> , (1993), 68:3:327-332.	
*		Chang YN et al., The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements. <i>J Virol</i> 64(1):264-77, Jan 1990.	
*		Chu RS et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. <i>J Exp Med</i> 186(10):1623-31, 17 Nov 1997.	
*		Cowdery JS et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. <i>J Immunol</i> 156(12):4570-5, 15 Jun 1996.	
*		Crosby et al., The Early Responses Gene FGFI-C Encodes a Zinc Finger Transcriptional Activator and is a Member of the GCGGGGGCG (GSG) Element-Binding Protein Family. <i>Mol. Cell. Biol.</i> 2:3835-3841, 1991.	
*	✓	Crystal, Transfer of Genes to Humans: Early Lessons and Obstacles to Success. <i>Science</i> , Vol. 270, pp. 404-410, 1995.	

FORM PTO-1449 (Modified)		ATTY. DOCKET NO.	SERIAL NO
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		C1039/7042	
		APPLICANT Krieg et al.	
		FILING DATE Herewith	GROUP 1635
* 93		D'Andrea A et al., Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. <i>J Exp Med</i> 178(3):1041-8, 1993.	
* 93		Englisch et al., Chemically Modified Oligonucleotides as Probes and Inhibitors, <i>Angew. Chem. Int. Ed. Engl.</i> , 30:613-629, 1991.	
*		Erb KJ et al., Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. <i>J Exp Med</i> 187(4):561-9, 16 Feb 1998.	
*		Etlinjer, Carrier sequence selection - one key to successful vaccines, <i>Immunology Today</i> , Vol. 13, 2:52-55, 1992.	
*		Fox RI, Mechanism of action of hydroxychloroquine as an antirheumatic drug. <i>Chemical Abstracts</i> , 120:15, Abstract No. 182630 (April 29, 1994).	
*		Gura, T., Antisense Has Growing Pains. <i>Science</i> (1995), 270:575-576.	
*		Hadden J et al., Immunostimulants. <i>TIPS</i> , (1993), 141:169-174.	
*		Hadden J et al., Immunopharmacology, <i>JAMA</i> , (1992) 268:20:2964-2969.	
*		Halpern MD et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. <i>Cell Immunol</i> 167(1):72-8, 1996.	
*		Hatzfeld J., Release of Early Human Hematopoietic Progenitors from Quiescence by Antisense Transforming Growth Factor β 1 or Rb Oligonucleotides, <i>J. Exp. Med.</i> , (1991) 174:925-929.	
*		Highfield PE, Sepsis: the More, the Murkier. <i>Biotechnology</i> , 12:828, August 12, 1994.	
*		Hoeffler JP et al., Identification of multiple nuclear factors that interact with cyclic adenosine 3',5'-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions. <i>Mol Endocrinol</i> 5(2):256-66, Feb 1991.	
*		Iguchi-Ariga SM and Shaffner W, CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. <i>Genes Dev</i> 3(5):612-9, May 1989.	
*		Iverson, P., et al., "Pharmacokinetics of an Antisense Phosphorothioate Oligodeoxynucleotide against reve from Human Immunodeficiency Virus Type 1 in the Adult male Rate Following Single Injections and Continuous Infusion", <i>Antisense Research and Development</i> , (1994), 4:43-52	
*		Ishikawa R et al., IFN induction and associated changes in splenic leukocyte distribution. <i>J Immunol</i> 150(9):3713-27, 1 May 1993	
*		Jakway JP et al., Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide, and other bacterial products. <i>J Immunol</i> 137(7):2225-31, 1 Oct 1986.	
*		Jaroszewski JW and Cohen JS, Cellular uptake of antisense oligonucleotides. <i>Adv Drug Delivery Rev</i> 6(3):235-50, 1991.	
*		Kimura Y et al., Binding of Oligoguanylate to Scavenger Receptors Is Required for Oligonucleotides to Augment NK Cell Activity and Induce IFN, <i>J. Biochem.</i> , Vol. 116, 5:991-994, 1994.	
*		Kline JN et al., CpG motif oligonucleotides are effective in prevention of eosinophilic inflammation in a murine model of asthma. <i>J Invest Med</i> 44(7):380A, 1996.	
*		Kline JN et al., Immune redirection by CpG oligonucleotides. Conversion of a Th2 response to a Th1 response in a murine model of asthma. <i>J Invest Med</i> 45(3):282A, 1997.	
*		Kline JN et al., CpG oligonucleotides can reverse as well as prevent Th2-mediated inflammation in a murine model of asthma. <i>J Invest Med</i> 45(7):298A, 1997.	
* ✓		Klinman DM et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. <i>Proc Natl Acad Sci USA</i> 93(7):2879-83, 1996.	

FORM PTO-1449 (Modified)		ATTY. DOCKET NO.	SERIAL NO
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		C1039/7042	
		APPLICANT Krieg et al.	
		FILING DATE Herewith	GROUP 1635
*		Krieg AM, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. <i>J Lab Clin Med</i> 128(2):128-33, 1996.	
*		Krieg AM et al., Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. <i>Antisense Res Dev</i> 1(2):161-71, Summer 1991.	
*		Krieg AM et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. <i>Antisense Nucleic Acid Drug Dev</i> 6(2):133-9, Summer 1996.	
*		Krieg AM et al., "Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy", <i>Proc. Natl. Acad. Sci.</i> , (1993), 90:1048-1052	
*		Krieg AM et al., "CpG DNA: A Pathogenic Factor in Systemic Lupus Erythematosus?", <i>Journal of Clinical Immunology</i> , (1995) 15:6:284-292	
*		Krieg AM et al., "Phosphorothioate Oligodeoxynucleotides: Antisense or Anti-Protein?", <i>Antisense Research and Development</i> , (1995), 5:241	
*		Krieg AM et al., "Leukocyte Stimulation by Oligodeoxynucleotides", <i>Applied Antisense Oligonucleotide Technology</i> , (1998), 431-448	
*		Krieg AM et al., CpG motifs in bacterial DNA trigger direct B-cell activation. <i>Nature</i> 374:546-9, 1995.	
*		Krieg AM et al., "The role of CpG dinucleotides in DNA vaccines", <i>Trends in Microbiology</i> , Vol. 6, pp. 23-27, Jan 1998.	
*		Krieg AM et al., "A Role for Endogenous Retroviral Sequences in the Regulation of Lymphocyte Activation, the <i>Journal of Immunology</i> , Vol. 143, 2448-2451,	
*		Kuramoto et al., Oligonucleotide Sequences Required for Natural Killer Cell Activation, <i>Jpn. J. Cancer Res.</i> , 83:1128-1131, November 1992.	
*		Leonard et al., Conformation of Guanine 8-Oxoadenine Base Pairs in the Crystal Structure of d(CGCGAATT(08A)GCG). <i>Biochemistry</i> , 31(36):8415-8420, 1992.	
*		Macfarlane DE and Manzel L, Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. <i>J Immunol</i> 160(3):1122-31, Feb 1 1998.	
*		Mastrangelo et al. <i>Seminars in Oncology</i> . Vol. 23, 1:4-21, 1996.	
*		Matson S and Krieg AM, Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides. <i>Antisense Res Dev</i> 2(4):325-30, Winter 1992.	
*		McIntyre KW et al., A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation. <i>Antisense Res Dev</i> 3(4):309-22, Winter 1993.	
*		Messina et al., The Influence of DNA Structure on the <i>in vitro</i> Stimulation of Murine Lymphocytes by Natural and Synthetic Polynucleotide Antigens. <i>Cellular Immunology</i> , 147:148-157, 1993.	
*		Messina et al., Stimulation of <i>in vitro</i> Murine Lymphocyte Proliferation by Bacterial DNA. <i>J. Immunol.</i> , Vol. 147, 6:1759-1764, September 15, 1991.	
*		Mojcik, C., et al., "Administration of a Phosphorothioate Oligonucleotide Antisense Murine Endogenous Retroviral MCF env Causes Immune Effect in vivo in a Sequence-Specific Manner", <i>Clinical Immunology and Immunopathology</i> , (1993), 67:2:130-136	
*		Mottram et al., A novel CDC2-related protein kinase from leishmania mexicana LmmCRK1 is post-translationally regulated during the life cycle. <i>J. Biol. Chem.</i> 268:28, 21044-21052 (October 1993).	
*		<i>New England Biolabs 1988-1989 Catalog</i>	
*		Nyce JW and Metzger WJ, DNA antisense therapy for asthma in an animal model. <i>Nature</i> 385:721-725, 20 Feb 1997.	

FORM PTO-1449 (Modified)		ATTY. DOCKET NO.	SERIAL NO
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		C1039/7042	
		APPLICANT Krieg et al.	
		FILING DATE Herewith	GROUP 1635
* 928		Pisetsky, D., "Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides", <i>Molecular Biology Reports</i> , (1993) 18:217-221	
*		Pisetsky et al., Stimulation of Murine Lymphocyte Proliferation by a Phosphorothioate Oligonucleotide with Antisense Activity for Herpes Simplex Virus. <i>Life Science</i> , Vol. 54, pp. 101-107 (1994).	
*		Pisetsky, The Immunological Properties of DNA. <i>The Journal of Immunology</i> , pp. 421-423 (1996).	
*		Pisetsky, Immunological Consequences of Nucleic Acid Therapy, <i>Antisense Research and Development</i> , 5:219-225 (1995).	
*		Raz E et al., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. <i>Proc Natl Acad Sci USA</i> 93(10):5141-5, 14 May 1996.	
*		Roman M et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. <i>Nat Med</i> 3(8):849-54, Aug 1997.	
*		Sato et al., Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization, <i>Science</i> , Vol. 273, pp. 352-354, 1996.	
*		Schnell et al., Identification and characterization of a <i>Saccharomyces cerevisiae</i> gene (PAR1) conferring resistance to iron chelators. <i>Eur. J. Biochem.</i> , 200:487-493.	
*		Schwartz DA et al., Endotoxin responsiveness and grain dust-induced inflammation in the lower respiratory tract. <i>Am J Physiol</i> 267(5 Pt 1):L609-17, 1994.	
*		Schwartz DA et al., The role of endotoxin in grain dust-induced lung disease. <i>Am J Respir Crit Care Med</i> 152(2):603-8, 1995.	
*		Schwartz DA et al., CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. <i>J Clin Invest</i> 100(1):68-73, 1 Jul 1997.	
*		Shirakawa T et al., The inverse association between tuberculin responses and atopic disorder. <i>Science</i> 275(5296):77-9, 3 Jan 1997.	
*		Sparwasser T et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. <i>Eur J Immunol</i> 27(7):1671-9, Jul 1997.	
*		Stein CA et al., Oligonucleotides as inhibitors of gene expression: a review. <i>Cancer Research</i> , 48:2659-2668, 1988.	
*		Stull et al., Antigene, Ribozyme, and Aptamer Nucleic Acid Drugs: Progress and Prospects, <i>Pharmaceutical Res.</i> , Vol. 12, 4:465-483, 1995.	
*		Subramanian et al., Theoretical Considerations on the "Spine of Hydration" in the Minor Groove of d(CGCGAATTCGCG) d(GCGCTTAAGCGC): Monte Carlo Computer Simulation. <i>Proc. Nat'l. Acad. Sci. USA</i> , 85:1836-1840, 1988.	
*		Tanaka T et al., An antisense Oligonucleotide complementary to a sequence in IG2b increases G2b germline transcripts stimulates B cell DNA synthesis and inhibits immunoglobulin secretion. <i>J. Exp. Med.</i> , 175:597-607, 1992.	
*		Thorne PS., Experimental grain dust atmospheres generated by wet and dry aerosolization techniques. <i>Am J Ind Med</i> 25(1):109-12, 1994.	
*		Tokunaga T et al., Synthetic Oligonucleotides with Particular Base Sequences form the cDNA Encoding Proteins of <i>Mycobacterium bovis</i> BCG Induce Interferons and Activate Natural Killer Cells, <i>Microbiol. Immunol.</i> , Vol. 36, 1:55-66, 1992.	
*		Tokunaga et al., A Synthetic Single-Stranded DNA, Ply (dG, dC), Induces Interferon α/β and $-\gamma$, Augments Natural Killer Activity and Suppresses Tumor Growth. <i>Jpn. J. Cancer Res.</i> , 79:682-686, June 1988.	
*		Uhlmann et al., Antisense Oligonucleotides: A New Therapeutic Principle. <i>Chemical Reviews</i> , 90:543-584, 1990.	
* ✓		Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. <i>Nature</i> , 372:L333-335, 1994.	

FORM PTO-1449 (Modified)		ATTY. DOCKET NO.		SERIAL NO	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		C1039/7042			
		APPLICANT Krieg et al.			
		FILING DATE Herewith		GROUP 1635	
*		Wallace et al., Oligonucleotide probes for the screening of recombinant DNA libraries. <i>Methods in Enzymology</i> , 152:432-442 (1987).			
*		Weiss R., Upping the Antisense Ante: Scientists bet on profits from reverse genetics. <i>Science</i> , 139:108-109, 1991.			
*		Whalen R, DNA Vaccines for Emerging Infection Diseases: What If?, <i>Emerging Infectious Disease</i> , Vol. 2, 3:168-175, 1996.			
*		Wu GY et al., Receptor-mediated gene delivery and expression in vivo. <i>J. Biol. Chem.</i> , 263:14621-14624, 1988.			
*		Wu-Pong S., Oligonucleotides: Opportunities for Drug Therapy and Research. <i>Pharmaceutical Technology</i> , 18:102-114, 1994.			
*		Yamamoto S et al., DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. <i>Microbiol Immunol</i> 36(9):983-97, 1992.			
*		Yamamoto S et al., <i>In vitro</i> augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from <i>Mycobacterium bovis</i> BCG. <i>Jpn J Cancer Res</i> 79:866-73, Jul 1988.			
*		Yamamoto S., Mode of Action of Oligonucleotide Fraction Extracted from <i>Mycobacterium bovis</i> BCG, <i>Kekkaku</i> , Vol. 69, 9:29-32, 1994.			
*		Yamamoto S et al., Unique Palindromic Sequences in Synthetic Oligonucleotides are Required to Induce INF and Augment INF-Mediated Natural Killer Activity. <i>J. Immunol.</i> , Vol. 148, 12:4072-4076, June 15, 1992.			
*		Yamamoto T et al., Ability of Oligonucleotides with Certain Palindromes to Induce Interferon Production and Augment Natural Killer Cell Activity is Associated with Their Base Length. <i>Antisense Res. and Devel.</i> , 4:119-123, 1994.			
*		Yamamoto et al., Lipofection of Synthetic Oligodeoxyribonucleotide Having a Palindromic Sequence AACGTT to Murine Splenocytes Enhances Interferon Production and Natural Killer Activity. <i>Microbiol. Immunol.</i> , Vol. 38, 10:831-836, 1994.			
*		Yamamoto T et al., Synthetic Oligonucleotides with Certain Palindromes Stimulate Interferon Production of Human Peripheral Blood Lymphocytes <i>in vitro</i> . <i>Jpn. J. Cancer Res.</i> , 85:775-779, 1994.			
*		Yi, Ae-Kyung et al., IFN- γ Promotes IL-6 and IgM Secretion in Response to CpG Motifs in Bacterial DNA and Oligonucleotides, <i>The Journal of Immunology</i> , pp. 558-564 (1996).			
*		Yi, Ae-Kyung et al., Rapid Immune Activation by CpG Motifs in Bacterial DNA, <i>The Journal of Immunology</i> , pp. 5394-5402 (1996).			
*		Zhao Q et al., Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. <i>Blood</i> 84(11):3660-6, 1 Dec 1994.			
*		Zhao Q et al., Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. <i>Antisense Res Dev</i> 3(1):53-66, Spring 1993.			

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 08/738,652, filed October 30, 1996, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

EXAMINER	DATE CONSIDERED 2/16/03
----------	-------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICATION NO.: 09/630,319		ATTY. DOCKET NO.: C01039/70042
	FILING DATE: July 31, 2000		CONFIRMATION NO.: 5464
	APPLICANT: Krieg et al.		
	GROUP ART UNIT: 1635		EXAMINER: Jane J. Zara

Sheet 03 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
J3	B10	WO	01/12804	A2	Hybridon, Inc.	02/22/01	
	B11	GB	2216416A		Sandoz, Ltd.	11/10/89	
	B12	WO	01/02007	A1	The Reagents of the Univ. of California	01/11/01	
	B13	WO	01/12223	A2	Dynavax Tech. Corp.	02/22/01	
	B14	WO	00/21556	A1	Dynavax Tech. Corp.	04/20/00	
	B15	WO	01/55341	A2	The Reagents of the Univ. of California	08/02/01	
	B16	WO	01/68117	A2	Dynavax Tech. Corp.	09/20/01	
	B17	WO	01/68116	A2	Dynavax Tech. Corp.	09/20/01	
	B18	WO	01/68078	A2	Dynavax Tech. Corp.	09/20/01	
	B19	WO	01/68077	A2	Dynavax Tech. Corp.	09/20/01	
✓	B20	WO	01/68103	A2	Dynavax Tech. Corp.	09/20/01	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
J3	C10	Bayever, et al. (1993). <i>Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Initial Results of a Phase I Trial</i> , ANTISENSE RESEARCH AND DEVELOP. 3:383.	
	C11	Cossum et al. (1993). <i>Pharmacokinetics of a 14C-Labeled Phosphorothioate Oligonucleotide, ISIS 2105, after Intradermal Administration to Rats</i> , J. PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 269(1):89.	
	C12	Agrawal, et al. (1995). <i>Pharmacokinetics of Antisense Oligonucleotides</i> , CLIN. PHARMACOKINET 28(1):7.	
	C13	Krieg (2002). <i>CpG Motifs in Bacterial DNA and Their Immune Effects</i> , ANNU. REV. IMMUNOL. 20:709.	
✓	C14	Lagrange et al. <i>Immune Responses Directed Against Infectious and Parasitic Agents</i> , THE PRINCIPLE TYPES OF IMMUNE RESPONSES.	

RECEIVED

EXAMINER <u>J3</u>	DATE CONSIDERED <u>2/16/03</u>	OCT 08 2002
--------------------	--------------------------------	-------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).



FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICATION NO.: 09/630,319	ATTY. DOCKET NO.: C01039/70042
	FILING DATE: July 31, 2000	CONFIRMATION NO.: 5464
	APPLICANT: Krieg et al.	
	GROUP ART UNIT: 1635	EXAMINER: Jane J. Zara
Sheet _____ of _____		

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
J3		20010046967	A1	Van Nest	11/29/2001
					RECEIVED
					MAY 01 2002
					TECH CENTER 1600/2900
<div>COPY OF PAPERS ORIGINALLY FILED</div>					

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	

EXAMINER J3	DATE CONSIDERED 2/16/03
-----------------------	-----------------------------------

#1 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered
Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application. Serial No. _____ filed _____ and
relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications)

Express Mail Label No. EL711219

U.S. PTO
09/630319
07/31/96

FORM PTO-1449 (Modified)	ATTY. DOCKET NO.	SERIAL NO
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	C1039/7042	09/630,319

APPLICANT Krieg et al.
FILING DATE Herewith
GROUP 1635

U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate
*	93	3,906,092	09/16/75	Hilleman et al.			
*		5,248,670	09/28/93	Draper et al.	514	44	
*		5,585,479	12/17/96	Hoke et al.	536	24.5	
*		5,663,153	09/02/97	Hutcherson et al.	514	44	
*		5,723,335	03/03/98	Hutcherson et al.	435	375	
*		5,786,189	07/28/98	Locht et al.	435	172.3	
*		5,849,719	12/15/98	Carson et al.	514	44	10/04/96

FOREIGN PATENT DOCUMENTS

	Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No	
*	WO 91/12811	09/05/91	PCT	A61K	31/70		
*	0468520 A3	01/29/92	EPO	A61K	31/70		
*	WO 92/03456	03/05/92	PCT	C07H	15/12		
*	WO 92/18522	10/29/92	PCT	C07H	21/00		
*	WO 92/21353	12/10/92	PCT	A61K	31/70		
*	0302758 81	03/16/94	EPO	C12N	15/37		
*	WO 94/19945	09/15/94	PCT	A01N	43/04		
*	WO 95/05853	03/02/95	Regents of the University of CA				
*	WO 95/26204	10/95	PCT	A61K	48/00		
*	WO 96/02555	02/01/96	PCT				
*	WO 96/35782	11/14/96	Applied Research Systems				
*	WO 97/28259	08/07/97	PCT	C12N	15/00		
*	WO 98/18810	05/07/98	PCT	C07H	21/00		
*	WO 98/37919	09/03/98	PCT	A61K	49/00		
*	WO 98/40100	09/17/98	PCT	A61K	39/39		
*	WO 98/52581	11/26/98	PCT	A61K	35/00		
*	WO 98/14210	04/09/98	PCT	A61K	39/35		